Abstract
Recombinant leukocyte A interferon used as single agent therapy (7.5 X 10(6) units/m2 three times weekly intramuscularly) showed very limited clinical efficacy in patients with advanced colo-rectal carcinoma. No objective tumour regressions were documented in 15 evaluable patients, although three patients demonstrated a stable disease status after 12 weeks of treatment. Neither were any objective tumour regressions registered in 13 patients during subsequent combined therapy with Recombinant Leukocyte A Interferon and cimetidine (1 000 mg/day orally). Two of the 3 patients maintained their stable disease status. No change in natural killer (NK) cell activity or in antibody dependent cellular cytotoxicity (ADCC) of peripheral blood mononuclear cells was seen during the two treatment periods.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
